Cencora, Inc.

Cencora, Inc., a US-based pharmaceutical preparation manufacturing company, has actively reported its carbon emissions and established climate commitments.

In 2025, Cencora's Scope 1 emissions were 189,955,000 kg CO2e, and its market-based Scope 2 emissions were 79,881,000 kg CO2e. Scope 3 emissions for the same year totalled 46,143,672,000 kg CO2e. In 2024, the company reported Scope 1 emissions of 135,087,000 kg CO2e and market-based Scope 2 emissions of 79,063,000 kg CO2e. Their Scope 3 emissions for 2024 were 40,504,539,000 kg CO2e, which included 39,446,178,000 kg CO2e from purchased goods and services, 625,837,000 kg CO2e from upstream transportation and distribution, and 120,237,000 kg CO2e from the end-of-life treatment of sold products. For 2023, Cencora's Scope 1 emissions were 108,712,000 kg CO2e and market-based Scope 2 emissions were 87,492,000 kg CO2e. In 2022, the company's Scope 1 emissions were 124,045,000 kg CO2e, market-based Scope 2 emissions were 87,642,000 kg CO2e, and Scope 3 emissions amounted to 23,627,236,000 kg CO2e.

Cencora is committed to reducing its absolute Scope 1 and Scope 2 greenhouse gas emissions by 54.6% by FY2032, using a FY2019 base year. This target is considered consistent with keeping global warming to 1.5°C, as validated by the Science Based Targets initiative (SBTi). The company also aims to achieve net-zero emissions for Scope 1 and Scope 2 by 2050. Furthermore, Cencora has committed that 82% of its suppliers by spend, covering purchased goods and services, will have science-based targets by FY2027.